No severe complications with presbyopia inlay

Article

Implantation of an intracorneal inlay (Kamra, AcuFocus) modified the normal structure of the corneal layer of the eye but did not cause severe complications in a recent small study.

Implantation of an intracorneal inlay (Kamra, AcuFocus) modified the normal structure of the corneal layer of the eye but did not cause severe complications in a recent small study.

Professor Jorge L. Alió, MD, PhD, FEBO, and colleagues discovered that keratocyte activation was the most common negative visual outcome in their study. Confocal microscopy helps assess corneal layer changes over time after the device is inserted, they said.

The researchers embedded one of three models (ACI 7000, 7000T and 7000PDT) of the inlay in 12 eyes of 12 patients and performed confocal microscopy to examine them 6 months later. During the follow-up period, they also looked at 4 more eyes of 4 patients in whom the device was removed.

In the eyes that received the inlay, mean epithelial thickness was 54.6 ± 22 μm. The investigators detected the subbasal nerve plexus in 10 patients.

The corneal nerves per unit area were 2.73 ± 2.1 sprouts/mm2. The scientists found the branch pattern in 8 patients.

The mean keratocyte density value was 540 ± 210 cells/mm2. The researchers found a low grade of keratocyte activation in all patients.

Among the eyes in which the device was explanted, the mean wound healing opacity was 1,092.75 ± 1,877.35 μm/pixel.

The authors said they have no financial or proprietary interests related to their study.

This study can be found in the Journal of Refractive Surgery.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.